Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -270.93% | 30.19% | -2,366.86% | 105.34% | 204.02% |
| Total Depreciation and Amortization | -3.24% | -4.57% | -2.28% | -3.89% | -19.92% |
| Total Amortization of Deferred Charges | 27.01% | 111.68% | 16.73% | 3.69% | -45.88% |
| Total Other Non-Cash Items | 1,162.12% | -7.28% | 1,079.63% | -232.46% | -111.29% |
| Change in Net Operating Assets | 172.55% | 134.18% | -38.97% | 4.38% | -160.18% |
| Cash from Operations | 253.02% | 377.77% | 16,336.59% | -44.82% | -84.92% |
| Capital Expenditure | -70.74% | -22.38% | -100.99% | 95.65% | 80.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -284.22% | -433.17% | -800.49% | -128.31% | -91.48% |
| Cash from Investing | -275.56% | -138.46% | -824.71% | -135.79% | -41.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.00% | 28.57% | 99.99% | 61.54% | 90.74% |
| Issuance of Common Stock | 765.42% | 531.68% | 4.48% | 351.05% | 365.81% |
| Repurchase of Common Stock | -652.92% | -21.36% | 100.00% | 25.97% | 88.41% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,498.31% | -- | -- | -- | 78.56% |
| Cash from Financing | 283.59% | 1,584.40% | 114.01% | 1,671.87% | 200.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 180.62% | 629.64% | 46.99% | -37.93% | -92.43% |